Evidence from well-planned, representative epidemiological surveys is scarce in many regions. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
32,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
Evidence from well-planned, representative epidemiological surveys is scarce in many regions. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The detailed estimates in this study constitute the best current basis for policymaking, planning, and allocation of health and welfare resources in dementia care. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Ageing of the population, together with population growth, has brought along an ample increase in the number of older individuals living with dementia and disabilities. 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
We included 18740 patients (10 205 women [54.5%]; mean [SD] age, 78.2[7.4] years), of which 4271 (22.8%) received at least one prescription for an antidepressant. 5 key findings →
Design: cohort study Participants: 18,740 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Slow gait speed has been shown to predict incident dementia and cognitive decline in older individuals. 1 key finding →
Design: longitudinal study Participants: 57,456 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Nowadays, Artificial Intelligence (AI) and machine learning (ML) have successfully provided automated solutions to numerous real-world problems. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Reducing the risk of dementia can halt the worldwide increase of affected people. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Worldwide costs of dementia are enormous and still inequitably distributed. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Among 2699 articles initially screened, 21 studies were included, encompassing over 1 million participants. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
During the 4-year follow-up, 134 individuals were diagnosed with dementia. 5 key findings →
Design: cohort study Participants: 2,220 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Despite mortality due to communicable diseases, poverty, and human conflicts, dementia incidence is destined to increase in the developing world in tandem with the ageing population. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Two of every three persons living with dementia reside in low- and middle-income countries (LMICs). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia is an increasing focus for policymakers, civil organizations and multidisciplinary researchers. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The huge costs of dementia worldwide place enormous strains on care systems and families alike.
Full summary, score breakdown and related studies → Original source Free full text
This study estimated the utilization and lifetime costs of formal care for AD dementia using longitudinal register data. 4 key findings →
Design: cohort Participants: 20,366 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The incidence of stroke and dementia are diverging across the world, rising for those in low- and middle-income countries and falling in those in high-income countries. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) and dementia are a global public health priority, and prevention has been highlighted as a pivotal component in managing the dementia epidemic. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
In our dataset search, we identified 108 910 people with a record indicating dementia at any time. 5 key findings →
Design: cohort study Participants: 9,819 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Dementia is receiving increasing attention from governments and politicians. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Observational population studies indicate that prevention of dementia and cognitive decline is being accomplished, possibly as an unintended result of better vascular prevention and healthier lifestyles. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Identification of modifiable risk factors provides a crucial approach to the prevention of dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Worldwide costs of dementia are enormous and distributed inequitably. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We found a 2- to 3-fold geographical variation in dementia odds in Sweden, after twin random effects-likely to capture genetic and shared environmental variance-were removed. 5 key findings →
Participants: 27,680 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We increased the findability, accessibility, interoperability and reusability (FAIR) status of the cohorts through harmonization of data across cohorts, implementation of medical imaging repositories for scan management, implementation of the Personal Health Train infrastructure and provision of meta-data in existing cohort catalogues. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
In the following brief report, we examined gender differences in incidence rates of any dementia, Alzheimer's disease (AD) alone, and non-Alzheimer's dementia alone in 16,926 women and men in the Swedish Twin Registry aged 65+. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 32,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 32,580 records, built mostly from automated pulls of Europe PMC (66.9% of the library) and OpenAlex (15.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,045 records (3.2% of the library) are not peer-reviewed — 966 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events
Last updated